TABLE 1.
Patient Characteristics by PGD Grade
| Variable | PGD Grade 0/1 (n = 41) |
PGD Grade 2/3 (n = 30) |
P Value |
|---|---|---|---|
| Recipient factors | |||
| Age, y | 57.9 ±11.4 | 54 ± 12.8 | .17 |
| Female | 18 (43.9) | 18 (60.0) | .27 |
| Body mass index, kg/m2 | 25.2 ± 5.2 | 26.3 ± 5.5 | .41 |
| Body surface area, m2 | 1.9 ± 0.3 | 1.8 ± 0.2 | .47 |
| Smoking history | 20 (48.8) | 10 (33.3) | .29 |
| Hypertension | 17 (41.5) | 11 (36.7) | .87 |
| Diabetes | 14 (34.1) | 7 (23.3) | .47 |
| Etiology of lung failure | |||
| COPD/CPFE | 13 (31.7) | 4 (13.3) | .13 |
| Interstitial lung disease | 10 (24.4) | 6 (20.0) | .88 |
| COVID-19 ARDS | 8 (19.5) | 5 (16.7) | 1.00 |
| Pulmonary arterial hypertension | 6 (14.6) | 6 (20.0) | .78 |
| Connective tissue disease | 2 (4.9) | 5 (16.7) | .21 |
| Other | 2 (4.9) | 4 (13.3) | .40 |
| Laboratory | |||
| Hemoglobin, g/dL | 12.1 ± 2.5 | 11.6 ± 2.3 | .37 |
| White blood cell, 1000/mm3 | 9.4 ± 4.0 | 9.4 ± 3.5 | .96 |
| Platelets, 1000/mm3 | 239.7 ± 98.9 | 284.6 ± 90.2 | .05 |
| Sodium, mEq/L | 139.6 ± 2.8 | 139.4 ± 3.2 | .80 |
| BUN, mg/dL | 14.8 ± 5.5 | 13.2 ± 4.8 | .19 |
| Creatinine, mg/dL | 0.77 ± 0.23 | 0.77 ± 0.22 | .99 |
| AST, U/L | 27.8 ± 22.2 | 24.0 ± 10.6 | .39 |
| ALT, U/L | 20.3 ± 16.7 | 18.9 ±11.7 | .69 |
| Albumin, g/dL | 3.9 ± 0.5 | 3.9 ± 0.5 | .54 |
| Total bilirubin, mg/dL | 0.7 ± 0.5 | 0.5 ± 0.3 | .07 |
| INR | 1.1 ± 0.3 | 1.1 ± 0.1 | .37 |
| Arterial blood gas | |||
| pH | 7.36 ± 0.06 | 7.36 ± 0.08 | .87 |
| Paco2 | 49.6 ± 10.6 | 51.2 ± 15.1 | .63 |
| Pao2 | 264.1 ± 125.1 | 297.0 ±111.1 | .27 |
| Donor | |||
| Age, y | 33.5 ± 12.5 | 36.0 ± 12.3 | .41 |
| Female | 18 (43.9) | 10 (33.3) | .51 |
| Cause of death | |||
| Anoxia | 17 (41.5) | 14 (46.7) | .85 |
| Head trauma | 17 (41.5) | 9 (30.0) | .46 |
| Other | 7 (17.1) | 7 (23.3) | .72 |
Values are presented as mean ± SD or n (%). ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CPFE, combined pulmonary fibrosis and emphysema; INR, international normalized ratio; PGD, primary graft dysfunction.